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Commentary
The Collegium Ramazzini first called for a 
universal ban on the mining, manufacture, 
and use of asbestos more than a decade ago 
(Collegium Ramazzini 1999). All forms of 
asbestos are now banned in 52 countries, and 
safer products have replaced many materials 
that once were made with it. Nonetheless, a 
large number of countries still use, import, 
and export asbestos and asbestos-containing 
products. In many countries that have banned 
other forms of asbestos, the so-called controlled 
use of chrysotile asbestos is exempted from the 
ban, an exemption that reflects the political 
and economic influence of the asbestos mining 
and manufacturing industry lobbies.
All forms of asbestos cause asbestosis, a 
progressive, debilitating fibrotic disease of 
the lungs. All forms of asbestos also cause 
malignant mesothelioma and lung and laryn-
geal cancers, and may cause ovarian, gastro-
intestinal, and other cancers (Straif et al. 
2009). More than 20 years ago, asbestos 
was declared a proven human carcinogen by 
the U.S. Environmental Protection Agency 
(U.S. EPA 1986), the International Agency 
for Research on Cancer (1977) of the World 
Health Organization (WHO), and the U.S. 
National Toxicology Program (NTP 1980). 
The scientific community is in overwhelming 
agreement that there is no safe level of expo-
sure to asbestos (Welch 2007; Welch et al. 
2009). Moreover, there is no evidence of a 
threshold level below which there is no risk of 
mesothelioma (Hillerdal 1999).
The Asbestos Cancer Pandemic
Occupational exposures to asbestos. About 
125 million people around the world are 
exposed to asbestos in their work environments 
(WHO 2006), and many millions more work-
ers have been exposed to asbestos in years past. 
As noted by Stayner et al. (1997), the U.S. 
National Institute for Occupational Safety 
and Health (NIOSH) has estimated that cur-
rent occupational exposures to asbestos, even 
at the U.S. Occupational Safety and Health 
Administration (OSHA) permissible exposure 
limit, will cause five deaths from lung cancer 
and two deaths from asbestosis in every 1,000 
workers exposed for a working lifetime.
In 2000, an estimated 43,000 deaths world-
wide resulted from malignant mesothelioma, 
and a much larger number of lung cancer deaths 
were due to occupational exposures to asbestos 
(Driscoll et al. 2005). Population-attributable 
risk for lung cancer among males exposed to 
asbestos ranges between 10% and 20% (Albin 
et al. 1999). An estimated 20,000 asbestos-
related lung cancers and 10,000 cases of 
mesothelioma occur annually across the popu-
lation of Western Europe, Scandinavia, North 
America, Japan, and Australia (Tossavainen 
2000). The national incidence rates for meso-
thelioma in Australia are the highest in the 
world (Leigh and Driscoll 2003).
In the United Kingdom, at least 3,500 
people die from asbestos-related illnesses each 
year, and this number is expected to increase 
to 5,000 in future years. Asbestos accounts 
for more than half of the work-related cancer 
deaths in Great Britain (Rushton et al. 2008). 
The British mesothelioma death rate is now 
the highest in the world, with 1,749 deaths 
in men (1 in 40 of all cancer deaths in men 
< 80 years of age) and 288 in women in 2005 
(Rake et al. 2009). The projected lifetime risk 
of fatal mesothelioma in all British men born 
in the 1940s is 0.59%, or about 1 in 170 of all 
deaths. By 2050, there will have been approxi-
mately 90,000 deaths from mesothelioma in 
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fact, chrysotile has accounted for > 95% of all the asbestos used globally. 
oBjective: We examined and evaluated the literature used to support the exemption of chrysotile 
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asbestos mining and manufacturing industry.
discussion: All forms of asbestos, including chrysotile, are proven human carcinogens. All forms 
cause malignant mesothelioma and lung and laryngeal cancers, and may cause ovarian, gastro-
intestinal, and other cancers. No exposure to asbestos is without risk. Illnesses and deaths from 
asbestos exposure are entirely preventable.
conclusions: All countries of the world have an obligation to their citizens to join in the inter-
national endeavor to ban the mining, manufacture, and use of all forms of asbestos. An inter-
national ban is urgently needed. There is no medical or scientific basis to exempt chrysotile from the 
worldwide ban of asbestos. 
key words: asbestos, asbestos cancer pandemic, asbestos-related diseases, ban, cancer, chrysotile, 
controlled use, disinformation, mesothelioma, product defense. Environ Health Perspect 118:897–901 
(2010). doi:10.1289/ehp.1002285 [Online 1 July 2010]
LaDou et al.
898 volume 118 | number 7 | July 2010 • Environmental Health Perspectives
Great Britain, 65,000 occurring after 2001 
(Hodgson et al. 2005).
Environmental exposures to asbestos. 
Nonoccupational, environmental exposure to 
asbestos from the use of construction materials 
that contain asbestos is also a serious and often 
neglected problem throughout the world. In 
developed countries, large quantities of asbestos 
remain as a legacy of past construction prac-
tices in many thousands of schools, homes, and 
commercial buildings. In developing countries, 
where asbestos is used today in large quantities 
in construction, asbestos-contaminated dust 
is now accumulating in thousands of com-
munities, with virtually all people burdened 
with asbestos fibers in their lungs and bodies 
(Brophy et al. 2007; Kazan-Allen 2005).
Both community-based and industrial 
exposures to asbestos and asbestiform fibers 
increase risks for mesothelioma (Pasetto 
et al. 2005). In a study of women residing 
in Canadian asbestos-mining communities, 
Camus et al. (1998) found a 7-fold increase 
in the mortality rate from pleural cancer. In 
California, residential proximity to naturally 
occurring asbestos was significantly associated 
with increased risk of mesothelioma (Pan et al. 
2005); the risk of mesothelioma decreased 
approximately 6.3% for every 10-km increase 
in residential distance from the nearest asbes-
tos source. Driece et al. (2009) reported that 
environmental exposures to asbestos waste on 
the surfaces of roads and yards in a contami-
nated community of 130,000 residents in the 
Netherlands result in several cases of malig-
nant mesothelioma each year. The currently 
observed increase in female cases of mesothe-
lioma in the United Kingdom, many with 
no occupational exposure to asbestos, sug-
gests widespread environmental contamina-
tion (Rake et al. 2009). In a study in Libby, 
Montana, (Vinikoor et al. 2010), respiratory 
symptoms were positively associated with the 
frequent handling of vermiculite insulation. 
Residents of this mining community who were 
children when the mine closed experienced 
respiratory symptoms associated with asbestos-
contaminated vermiculite exposure. 
Science and Controversy
Asbestos is a general term applied to certain 
fibrous minerals of two configurations: serpen-
tine and amphibole. The only type of asbestos 
derived from serpentine minerals, chrysotile 
(also known as white asbestos), accounts for 
100% of the asbestos used in the world today 
(Natural Resources Canada 2006). Amphibole 
minerals include five asbestos species: amosite, 
crocidolite, tremolite, anthophyllite, and 
actinolite. Two of these are the most com-
mercially valuable forms: amosite, or brown 
asbestos, and crocidolite, or blue asbestos. 
Other minerals sometimes containing fibers 
that are not defined by industry as asbestos, 
such as erionite, taconite, and talc, are clearly 
capable of causing asbestos diseases, as are cer-
tain man-made fibers, including some nano-
fibers (Dikensoy 2008; Ryman-Rasmussen 
et al. 2009; Sanchez et al. 2009). The thermal 
and chemical resistance and tensile strength 
of asbestos fibers gave rise to a burgeon-
ing industry before their detrimental health 
effects—which often take years and decades to 
appear—became known.
The asbestos industry has relied on scien-
tific debates over the roles of fiber types, 
viruses, and genetics in the development of 
mesothelioma to obfuscate the problem of 
asbestos-related disease (Castleman et al. 
1998). The risk of lung cancer among workers 
exposed to chrysotile asbestos increases slightly 
with exposure to longer and thinner fibers 
(Loomis et al. 2009). However, efforts to use 
statistical models to characterize relative can-
cer potencies for asbestos fiber types and sizes 
have not been able to overcome limita tions 
of the exposure data. Epidemiologic, experi-
mental, and molecular evidence suggests that 
the arguments for the role of fiber size relative 
to dose, dose–response effect, and genetic sus-
ceptibility are fraught with enormous uncer-
tainties (Terracini 2007; Tomatis et al. 2007). 
Scientists from NIOSH (2010) contend that 
the uncertainties have been so great that these 
estimates should not be used to determine 
occupational and environ mental health policy 
until the agency can perform further research. 
The U.S. EPA has rejected and discontinued 
work on its proposed methods for quantifying 
potency factors for partitioned asbestos fiber 
types and sizes (Silverstein et al. 2009).
Concern has been raised that mesothe-
lioma deaths might be partly attributable to 
polio virus vaccines used during the 1950s and 
1960s that were contaminated with simian 
virus 40 (SV40), a monkey virus that is tumori-
genic in rodents (Leithner et al. 2006; Price 
et al. 2007). However, sex- and age-specific 
trends in pleural mesothelioma incidence rates 
were not consistent with an effect of exposure 
to SV40-contaminated polio virus vaccine. In 
addition, studies reporting a high prevalence of 
SV40 DNA in human tumors were based on 
molecu lar assays that are prone to false-positive 
results (Lopez-Rios et al. 2004).
Some researchers have suggested that sus-
ceptibility to asbestos-related diseases is related 
to genetic differences between individuals 
within populations. A study of a mesothe-
lioma clustering in Turkey advocated the role 
of genetic susceptibility and familial inheri-
tance in the etiology of the disease (Roushdy-
Hammady et al. 2001; Saracci and Simonato 
2001). A genetic factor identified in three vil-
lages in Cappadocia, Turkey, where 50% of 
individuals die of mesothelioma, may con-
tribute to the high incidence of the disease. 
In these villages, genetic predisposition for 
mesothelioma works together with erionite 
(Carbone and Rdzanek 2004). However, in 
European studies the low proportion of famil-
ial cases does not suggest the influence of a 
large genetic component for mesothelioma in 
blood relatives (Ascoli et al. 2007).
Controversies such as these have helped 
to make the disease experiences of asbestos-
exposed workers and people in asbestos-
contaminated communities invisible and 
uncompensated, allowing the asbestos industry 
to escape accountability (Braun et al. 2003). 
The problem extends well beyond asbestos. 
“Product defense papers” are commissioned 
by a wide range of industries seeking to blunt 
regu lators’ efforts and to defeat the cases 
brought by plaintiffs. Even physician-scientists 
reporting on hazards of asbestos have been dis-
ciplined by their politically motivated govern-
ments (Joshi et al. 2009).
Industries have the resources to seed the 
literature with strategic science that is less likely 
to be subjected to the same scrutiny routinely 
applied to science that is explicitly case specific 
(Boden and Ozonoff 2008). Many articles, 
published primarily in toxicology journals, are 
termed “product defense” science articles and 
are frequently sponsored by asbestos interests 
such as the defendants in personal injury asbes-
tos litigation in the United States (Axelson et al. 
2003; Michaels 2008). These articles are distin-
guished from other science papers in that they 
are written by scientific consultants and con-
sulting firms that are approached and paid mil-
lions of dollars to publish and promote articles 
used to try to defeat liability claims (Michaels 
2006). General Motors, Ford, and Chrysler 
sponsored the writing of review articles and 
meta-analyses of previously published work, 
and paid almost $37 million between 2001 
and 2008 to scientist-consultants at ChemRisk 
and Exponent, Inc., for presentations of these 
papers at scientific meetings and expert testi-
mony on the articles (Dietz et al. v. ACandS 
Inc. et al. 2009). These companies were defen-
dants in damage suits brought by mechanics 
over their asbestos exposures and disease arising 
from automotive friction materials.
When there is consensus in the public 
health community about the health effects of 
a compound—particularly one that is as well 
researched as asbestos—government agen-
cies and other funders are not interested in 
additional research that will merely demon-
strate what is already known. The only people 
who have an incentive to continue to fund 
research on the health effects of chrysotile 
are those with an economic incentive to raise 
doubt about its harm. Sponsorship by parties 
involved in litigation leads to an imbalance in 
the literature (Michaels and Monforton 2007). 
As a result, subsequent literature reviews that 
report a predominance of articles reaching a 
certain conclusion may then mistakenly report 
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there is a new “consensus” in the literature 
when that consensus is an artifact of sponsor-
ship (Michaels 2009). Wealthy sponsors have 
simply paid to have more papers published.
A  Con f e r enc e  on  A sbe s t o s  and 
Mesothelioma was held in May 2010 and 
was sponsored by both plaintiff and defense 
lawyers who paid scientists to come to a 
resort center to discuss asbestos issues (Perrin 
Conferences 2010). The conference discussed 
matters on which there is broad scientific con-
sensus that are still questioned as part of the 
defense in litigation seeking to reject compen-
sation. Such conferences can serve to perpetu-
ate the illusion of uncertainty about issues 
for which there is ample evidence concerning 
the dangers of all forms of asbestos. Indeed, 
asbestos interests have a record of seizing 
opportunities to challenge the carcinogenicity 
of chrysotile, trying to create the impression 
that it is still a matter of legitimate scientific 
debate; this creates doubt about legitimate 
scientific findings and renders policy inter-
ventions unlikely (McCulloch and Tweedale 
2008). The complex ties of the asbestos indus-
try with international groups are numer-
ous and problematic (Ashford et al. 2002; 
Castleman 2001; LaDou 2004).
Chrysotile Asbestos
Chrysotile represents nearly 100% of the 
asbestos produced and used worldwide today 
(Natural Resources Canada 2006) and 95% 
of all the asbestos used worldwide since 1900 
(Virta 2005). There is general agreement 
among scientists and physicians, and wide-
spread support from agencies in countries 
around the world, that chrysotile causes various 
cancers, including mesothelioma and lung can-
cer (Agency for Toxic Substances and Disease 
Registration 2001; American Conference of 
Governmental Industrial Hygienists 2001; 
International Labour Organization 2006; 
International Social Security Association 2004; 
National Cancer Institute 2003; NTP 2004; 
OSHA 1994; United Nations Environment 
Program 1998; WHO 2006; World Trade 
Organization 2001].
Early suggestions and industry reports that 
chrysotile might be significantly less dangerous 
than other forms of asbestos have not been 
substantiated. Although chrysotile accounts 
for almost all the asbestos ever used, the asbes-
tos industry continues to claim that asbestos-
related cancers are the result of the amphibole 
varieties (McCulloch 2006). Defenders of 
the chrysotile asbestos industry contend that 
“exposure to chrysotile in a pure form seems 
likely to present a very low if any risk of meso-
thelioma” (Gibbs and Berry 2008).
The Chrysotile Institute (Montreal, 
Quebec, Canada), a registered lobby group for 
the Quebec asbestos mining industry, takes 
the position that chrysotile can be handled 
safely (Chrysotile Institute 2008). Numerous 
epidemiologic studies, case reports, controlled 
animal experiments, and toxicological studies 
refute the assertion that chrysotile is safe (Bang 
et al. 2006; Landrigan et al. 1999; Lemen 
2004b; Lin et al. 2007; Smith and Wright 
1996; Stayner et al. 1996; Tossavainen 1997). 
These studies demonstrate that the so-called 
controlled use of asbestos is a fallacy (Lemen 
2004a; Welch et al. 2009). Workers exposed 
to chrysotile fiber alone have excessive risks of 
lung cancer and mesothelioma (Frank et al. 
1998; Li et al. 2004; Mirabelli et al. 2008).
The Canadian Cancer Society (2010), the 
Canadian Medical Association (2009), and the 
Canadian Public Health Association (2010) 
oppose the export of asbestos to developing 
countries. The National Public Health Institute 
of Quebec has published 15 reports, all of them 
showing a failure to achieve “controlled use” of 
asbestos in Quebec itself (Takaro et al. 2010). 
Pat Martin, a member of Canada’s parliament 
and a former asbestos miner, asks, “If we in the 
developed world haven’t found a way to handle 
chrysotile safely, how can we expect them to do 
so in developing nations?” (Burki 2010).
Some countries have banned forms of 
asbestos no longer in use anywhere, yet they 
exempt the use of chrysotile. This exemp-
tion reflects the close relationship the asbestos 
industry has with many governments, the lack 
of public health information and regulation 
in these countries, and the lack of compensa-
tion for asbestos victims (Castleman and Joshi 
2007; Greenberg 2005; Kazan-Allen 2003). 
The toll in most countries still using large 
amounts of asbestos may never be fully ascer-
tained or recorded.
Current Production and Use 
of Asbestos
Despite all that is known about the dangerous 
and adverse health effects of asbestos, annual 
world production remains at > 2 million 
tons [U.S. Geological Survey (USGS) 2009]. 
Russia is now the leading producer of asbestos 
worldwide, followed by China, Kazakhstan, 
Brazil, Canada, Zimbabwe, and Colombia. 
These six countries accounted for 96% of the 
world production of asbestos in 2007. Russia 
has mines rich enough in asbestos deposits to 
last for > 100 years at current levels of pro-
duction (Encyclopedia of the Nations 2010). 
Most of the 925,000 tons of asbestos extracted 
annually in Russia is exported.
All forms of asbestos are now banned 
in 52 countries (International Ban Asbestos 
Secretariat 2010), including all European 
Union member countries. Nonetheless, these 
52 countries make up less than one-third of 
WHO member countries. A much larger 
number of WHO member countries still use, 
import, and export asbestos and asbestos-
containing products (WHO 2006). These are 
almost all countries in Asia, Eastern Europe, 
Latin America, and Africa. Most of the world’s 
people still live in countries where asbestos 
use continues, usually with few safeguards. 
More than 85% of the world production of 
asbestos is used today to manufacture products 
in Asia and Eastern Europe (Virta 2005). In 
developing countries, where too often there 
exists little or no protection of workers and 
communities, the asbestos cancer pandemic 
may be the most devastating. China is by far 
the largest consumer of asbestos in the world 
today, followed by Russia, India, Kazakhstan, 
Brazil, Indonesia, Thailand, Vietnam, and 
Ukraine (United Nations Statistics Division 
2009; USGS 2009).
Position of International 
Agencies on Asbestos
International organizations have condemned 
the continuing use of chrysotile asbestos. In 
2006, the WHO called for the elimination of 
diseases associated with asbestos. The WHO 
supports individual countries in developing 
national plans to ban asbestos and eliminate 
asbestos-related disease, stating that “the most 
efficient way to eliminate asbestos-related 
disease is to stop using all types of asbestos” 
(WHO 2007). The International Labour 
Organization (2006) expressed concern about 
an evolving epidemic of asbestos-related dis-
eases and passed a resolution to promote a 
worldwide asbestos ban. The World Trade 
Organization has accepted the conclusion that 
the “controlled use” of asbestos is a fallacy 
(Castleman 2002).
The Rotterdam Convention (2005) is an 
inter national agreement intended to regu-
late global trade in dangerous chemicals—
chemicals that have been banned or severely 
restricted because of their hazards to human 
health or the environment. It was entered 
into force in 2004, and 131 nations are cur-
rently Parties to the Convention. The goal 
is to protect the world’s most vulnerable 
countries—developing countries and coun-
tries with economies in transition—against 
importation of hazardous pesticides and other 
listed chemicals without their prior informed 
consent (PIC). 
PIC is the core principle of the Rotterdam 
Convention. This legally binding proce-
dure requires that govern ments in all coun-
tries be provided full information about the 
risks to health and the environment of each 
of the hazardous materials regulated by the 
Convention before importation. Annex III of 
the Rotterdam Convention lists the chemi-
cals—40 in number—currently covered by the 
Convention’s PIC requirement: 25 pesticides, 
4 severely hazardous pesticide formulations, 
and 11 industrial chemicals.
Repeated efforts to include chrysotile 
asbestos under the Rotterdam Convention 
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have failed, not because its Chemical Review 
Committee has not recommended the listing 
of chrysotile, but because of the Convention’s 
requirement for unanimity and as a result of 
the determined opposition of asbestos mining 
and manufacturing countries. At the 2008 
conference of parties on the Convention, 
Kazakhstan, Kyrgyzstan, Vietnam, Russia, and 
Zimbabwe opposed listing chrysotile asbestos 
in Annex III [IISD (International Institute for 
Sustainable Development) Reporting Services 
2008]. A few asbestos-importing countries 
thwarted the will of > 100 other countries.
The Need for a Universal Ban 
on Asbestos
The profound tragedy of the asbestos pan-
demic is that all illnesses and deaths related 
to asbestos are preventable. Safer substitutes 
for asbestos exist, and they have been intro-
duced successfully in many nations. Currently, 
asbestos cement products account for > 85% 
of world consumption (Virta 2005), and in 
about 100 countries, asbestos-containing pipes 
and sheets are manufactured to be used as low-
cost building materials (Tossavainen 2004). 
However, these asbestos cement water-pipe 
products could be replaced with ductile iron 
pipe, high-density polyethylene pipe, and 
metal-wire–reinforced concrete pipe. Many 
substitutes exist for roofing as well as interior 
building walls and ceilings, including fiber-
cement flat and corrugated sheet products that 
are made with polyvinyl alcohol fibers and 
cellu lose fibers. Virtually all of the polymeric 
and cellulose fibers used instead of asbestos 
in fiber-cement sheets are > 10 µm in diam-
eter and therefore non respirable (WHO 2005). 
For roofing, lightweight concrete tiles can be 
made and used in the most remote locations 
using locally available plant fibers, such as jute, 
hemp, sisal, palm nut, coconut coir, and wood 
pulp. Galvanized iron roofing and clay tiles are 
among the other alternative materials (World 
Bank Group 2009).
If global use of asbestos were to cease 
today, a decrease in the incidence of asbes-
tos-related diseases would become evident in 
approximately 20 years (WHO 2006). The 
asbestos cancer pandemic may take as many 
as 10 million lives before asbestos is banned 
worldwide and all exposure is brought to an 
end (LaDou 2004). But the world’s current 
production of asbestos continues at an alarm-
ing rate; therefore; these figures may not reflect 
the true burden of this pandemic.
An international ban on the mining and 
use of asbestos is urgently needed. The risks of 
exposure to asbestos cannot be controlled by 
technology or by regulation of work practices. 
Scientists, physicians, and responsible authori-
ties in countries allowing the use of asbestos 
should have no illusion that “controlled use” of 
chrysotile asbestos is an effective alternative to 
a ban on all use of asbestos (Castleman 2003; 
Egilman and Roberts 2004). Even the best 
systems of workplace controls cannot prevent 
occupational and environmental exposures 
to products in use, or exposures to asbestos 
discarded as waste. Safer substitute products 
are in use in countries all over the world where 
asbestos is banned.
To protect the health of all—now and 
in future environments—the Collegium 
Ramazzini again calls on all countries of the 
world to join in the international endeavor to 
ban the mining, manufacture, and use of all 
forms of asbestos.
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